Abstract

ZAFIRLUKAST: CHRONOTHERAPEUTIC APPROACH AND DETAILED PHARMACEUTICAL REVIEW

Padmaxi Bailpattar*, Naveen K. L. and Praveen Vijapur

ABSTRACT

Zafirlukast is one of promising medication used in the management and prophylactic treatment of bronchial asthma. It’s orally active, potent, selective and competitive cysteinyl leukotriene (csyLT) inhibitor (antagonist). Zafirlukast plays vital role in blocked of the effects of exogenous administered cysLTs and LTD4 released endogenously in response to physical and chemical stimuli. Drug is particularly effective in allergen induced and exercise induced asthma. Chronotherapeutic response by zafirlukast have shown to inhibit night time awakening improves PEF rates i.e nocturnal asthma. Zafirlukast have shown to alleviate the symptoms and decrement in lung function seen in nocturnal asthma. Mainly drug competes with the pro-inflammatory cysteinyl leukotrienes such as D4, E4 and C4 at cysLTR-1 to prevent inflammation induced by leukotrienes. Animal studies shown that Zafirlukast having antagonistic effects on leukotriene induced bronchial constriction in guinea pig trachea, lung parenchyma and isolated human bronchi.

Keywords: nocturnal asthma, chronotherapeutics, Pharmacokinetic. Zafirlukast. Leukotriene, Antagonist.